Posts by Maxx Chatsko
Article
Maxx’s Top Stock for May 2022
May 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in May 2022 serves as the linchpin of for biology-driven enterprises.
By Maxx Chatsko
Video
Maxx’s Top Stock for March 2022
Mar 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in March 2022 is on the cusp of ramping three high-growth brands large, underserved markets.
By Maxx Chatsko
Article
Interacting with Members and Refining My Frameworks
Feb 22, 2022
Speaking with members has helped me to fine-tune my research process with clearer communication in mind.
By Maxx Chatsko
Premium Advisor Update
Will Solid-State Batteries Live Up to the Hype?
Feb 8, 2022
By Maxx Chatsko
Video
Maxx’s Top Stock for February 2022
Feb 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in February 2022 has what might be the best technology stack and most methodical approach in molecular testing. That makes it well positioned...
By Maxx Chatsko
Premium Advisor Update
“Very High Risk” Isn’t Very Helpful
Jan 26, 2022
By Maxx Chatsko
Article
Wild Prediction for 2022: CRISPR Stocks Become Mortal Again
Jan 22, 2022
Emerging therapeutic modalities built on the enzymatic tool will be subject to the traditional risk-reward calculus facing drug developers.
By Maxx Chatsko
Premium Advisor Update
Should You Invest in Synthetic Biology Stocks?
Jan 14, 2022
By Maxx Chatsko
Podcast
5 Big Reveals from the 2022 JP Morgan Healthcare Conference
Jan 13, 2022
7investing Lead Advisors Simon Erickson and Maxx Chatsko discuss a handful of big reveals from the first few days of the 2022 JP Morgan Healthcare Conference.
By Maxx Chatsko
Video
Maxx’s Top Stock for January 2022
Jan 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in January 2022 is developing a novel technology platform that's well-positioned to address some of the biggest challenges facing gene therapy...
By Maxx Chatsko
Article
Dicerna Pharmaceuticals Deep Dive: October 2021
Dec 28, 2021
For the first time ever, we are releasing an active recommendation to the general public as three-time recommendation Dicerna Pharmaceuticals was acquired by Novo Nordisk in a $3.3 billion deal.
By Maxx Chatsko
Premium Advisor Update
Can Better Antibodies Disrupt Cell Therapy?
Dec 20, 2021
By Maxx Chatsko
Podcast
Investing in Emerging Markets with Perth Tolle
Dec 16, 2021
7investing Lead Advisors Matt Cochrane and Maxx Chatsko chat with Perth Tolle about investing in emerging markets as a global citizen who respects economic and personal freedoms.
Financial Services
Video
Maxx’s Top Stock for December 2021
Dec 1, 2021
7investing Lead Advisor Maxx Chatsko's top stock to buy in December 2021 has just de-risked the entire therapeutic modality of gene therapy -- and Wall Street is entirely misunderstanding the...
By Maxx Chatsko
Article
Think Long Term, but Focus on Your Five-Meter Targets
Nov 21, 2021
Take care of business before getting too carried. Invest in companies that do the same.
By Maxx Chatsko
Video
Maxx’s Top Stock for November 2021
Nov 1, 2021
7investing Lead Advisor Maxx Chatsko's top stock to buy in November 2021 is at the very beginning of an inflection point in its growth trajectory.
By Maxx Chatsko
Article
Navigating Inflation and Interest Rates with Your Hard-Earned Money
Oct 22, 2021
Even long-term investors should acknowledge the role that Fed policy is playing in stock valuations.
By Maxx Chatsko
Podcast
Blue-Sky Thinking in Synthetic Biology
Oct 19, 2021
What will it take for synthetic biology to live up to its promise? 7investing Lead Advisor Maxx Chatsko talks with visionary scientist Andrew Hessel about pushing the envelope of living technologies ...
By Maxx Chatsko
Premium Advisor Update
Drug Development is Risky. Let’s Count the Ways.
Oct 14, 2021
By Maxx Chatsko
Podcast
7investing Explains: How are Medical Devices and Genetic Tests Regulated?
Oct 14, 2021
Health care investors often focus on drug products, but medical devices present unique investing opportunities, too. 7investing Lead Advisors Simon Erickson, Dana Abramovitz, and Maxx Chatsko provide...
Health Care Technology
Article
Can Your Gene Editing Stocks Survive the End of Momentum?
Oct 8, 2021
There are both opportunities and challenges to modifying DNA for therapeutic applications, but objective information is scarce.
By Maxx Chatsko
Video
Maxx’s Top Stock for October 2021
Oct 1, 2021
7investing Lead Advisor Maxx Chatsko's Top Stock for October 2021 is one of the most undervalued drug developers on the market.
By Maxx Chatsko
Article
Why are $100 Billion Drug Developers Such Lousy Investments?
Sep 23, 2021
While 18 companies have crossed that valuation milestone, only one has consistently outperformed the S&P 500 after.
By Maxx Chatsko
Article
Give Your Thesis Time to Breathe, But Be Objective
Sep 22, 2021
Knowing when to sell an early-stage drug developer isn't easy, but it's nearly impossible when you're a cheerleader.
By Maxx Chatsko
Article
What’s Next for mRNA?
Sep 15, 2021
The therapeutic modality is well-suited to create vaccines for infectious diseases. What about other therapeutic areas?
By Maxx Chatsko
Premium Advisor Update
Annual 2021 Review: Maxx’s 7investing Recommendations
Sep 14, 2021
By Maxx Chatsko
Podcast
Bringing Synthetic Biology to Consumers, One Material at a Time
Sep 14, 2021
Sustainable materials might be the biggest market opportunity no one is talking about. 7investing Lead Advisor Maxx Chatsko chats with Bolt Threads CEO Dan Widmaier about the opportunities and...
By Maxx Chatsko
Article
The FDA Cracks Down on Safety for Multiple Drug Classes
Sep 10, 2021
The moves send a clear signal to drug developers, even if the immediate economic consequences are mostly limited.
By Maxx Chatsko
Podcast
7investing Market Focus: Why Are Investors So Optimistic? (8/24/21)
Sep 2, 2021
News that the FDA gave Pfizer (NYSE: PFE) full approval for its COVID-19 vaccine, as well as crude prices rallying caused all the major indexes to end the day in the green. Join Maxx Chatsko and...
By Maxx Chatsko
Podcast
7investing Market Focus: Why Long-Term Investors Don’t Worry on Red…
Sep 2, 2021
If there is one thing investors can predict, it is that there will be volatility in the stock market. Stocks can plummet 20% or more in a single day on no news. While that can be frustrating, it's...
By Daniel Kline
Video
Maxx’s Top Stock for September 2021
Sep 1, 2021
7investing Lead Advisor Maxx Chatsko's top stock to buy in September 2021 is a leading provider of genetic and molecular testing services.
By Maxx Chatsko
Article
What Will the Delta Variant Mean for the Stock Market?
Aug 22, 2021
Covid cases are up and that spooked some investors, but the effect may be short-lived.
By Daniel Kline
Article
Repligen Always Seems to Make the Right Moves
Aug 21, 2021
The bioprocess leader quietly keeps delivering for shareholders.
By Maxx Chatsko
Article
I Tracked Every Car-Related Expense for 8 Years. Here’s What…
Aug 18, 2021
What's the true cost of car ownership? My nerdy habit has provided some interesting answers.
By Maxx Chatsko
Podcast
7investing Market Focus: The Red Hot Rental Market (8/11/21)
Aug 17, 2021
Low interest rates and skyrocketing housing prices have been raising the roof on the rental market. What impact will this have on the overall US economy? 7investing lead advisors Dan Kline and Maxx...
By Daniel Kline
Premium Advisor Update
What Defines a Stock Market Bubble?
Aug 13, 2021
By Maxx Chatsko
Article
Will We Need a Covid Vaccine Booster Shot?
Aug 13, 2021
The companies that make the shot say yes, but the answer is more complicated.
By Maxx Chatsko
Podcast
7investing Market Focus: Simon’s Malls Are Returning Back to Normal…
Aug 10, 2021
Simon Property Group has disclosed its sales have now fully recovered to their 2019 levels. Post-pandemic, what items are consumers most interested in buying from malls? 7investing lead advisors Dan...
By Daniel Kline
Advisor Update
The 7investing Recommendation That Wasn’t
Aug 9, 2021
Maxx explains how red flags prevented him from recommending a seemingly promising biopharma stock to 7investing subscribers.
By Maxx Chatsko
Podcast
The 3 Frameworks for Evaluating Gene Editing Stocks
Aug 3, 2021
Most investors have heard about gene editing, but there are many differences between the major technology platforms. 7investing Lead Advisors Maxx Chatsko and Dan Kline introduce three simple...
By Daniel Kline
